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Abstract
Purpose Macrolide antibiotics, erythromycin, in particu-
lar, have been linked to the development of infantile
hypertrophic pyloric stenosis (IHPS). Our aim was to
conduct a systematic review of the evidence of whether
post-natal erythromycin exposure is associated with sub-
sequent development of IHPS.
Methods A systematic review of postnatal erythromycin
administration and IHPS was performed. Papers were
included if data were available on development (yes/no) of
IHPS in infants exposed/unexposed to erythromycin. Data
were meta-analysed using Review Manager 5.3. A random
effects model was decided on a priori due to heterogeneity
of study design; data are odds ratio (OR) with 95 % CI.
Results Nine papers reported data suitable for analysis;
two randomised controlled trials and seven retrospective
studies. Overall, erythromycin exposure was significantly
associated with development of IHPS [OR 2.45
(1.12–5.35), p = 0.02]. However, significant heterogeneity
existed between the studies (I2 = 84 %, p\ 0.0001). Data
on erythromycin exposure in the first 14 days of life was
extracted from 4/9 studies and identified a strong associa-
tion between erythromycin exposure and subsequent
development IHPS [OR 12.89 (7.67–2167), p\ 0.00001].
Conclusion This study demonstrates a significant associa-
tion between post-natal erythromycin exposure and
development of IHPS, which seems stronger when expo-
sure occurs in the first 2 weeks of life.
Keywords Pyloric stenosis  Erythromycin  Macrolide
antibiotics
Introduction
Infantile hypertrophic pyloric stenosis (IHPS) affects 1.9 of
every 1000 live births [1] making the condition the most
common cause of surgical intervention in the first 6 months
of life [2]. IHPS is characterised by hypertrophy of the
pylorus resulting in gastric outlet obstruction, leading to the
infant presenting with projectile vomiting and severe
dehydration.
Although genetics [3] and male sex [4] have been
identified as risk factors, the aetiology of IHPS is largely
unknown. Furthermore, changes in the incidence rates of
IHPS have led to the hypothesis that environmental factors
may have a role in the development of the condition [5].
Several studies have identified a strong relationship
between exposure to erythromycin and development of IHPS
[6]—with some studies identifying an eight to tenfold
increase in risk of developing IHPS when erythromycin was
administered in the first 2 weeks of life [7]. One theory is that
erythromycin interacts with the receptors of motilin, an
intestinal peptide that stimulates contraction of gut smooth
muscle. This interaction could therefore produce contraction
of the gastric and pyloric bulb, resulting in hypertrophy of the
pylorus [8]. However, other studies refute the association
between erythromycin treatment in infants and the devel-
opment of IHPS entirely, identifying no association [9].
The aim of this study was to perform a systematic
review and meta-analysis of published studies to clarify
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and quantify the relationship between any post-natal
exposure to erythromycin and the development of pyloric
stenosis. A second aim was to determine whether treatment
with erythromycin within the first 2 weeks of life increased
the magnitude of this association.
Methods
A systematic literature search was performed of all studies
published from1 January 1970 and1 July 2016, usingPubMed,
Ovid Medline, Embase and the Cochrane Library with the
medical subject heading (MeSH) terms and text words: (in-
fantile hypertrophic pyloric stenosisORpyloric stenosis) AND
(macrolide OR erythromycin) and similar variants. Search
criteria were limited to studies published in the English lan-
guage, and by age of subject (age less than 6 months) to ensure
that only infantile cases of pyloric stenosis were included for
analysis. Reference lists of included articles and abstract lists of
relevant national and internationalmeetingswere also searched
to identify other studies which could be included for analysis.
Studies were then assessed for inclusion by two authors
independently (LM, SE). Our aim was to ensure that all
robust studies which reported an association between ery-
thromycin exposure and subsequent development of IHPS
were included for analysis. Studieswere excluded for several
reasons; insufficient data available for analysis, unable to
extract suitable data to allow meta-analysis, type of macro-
lide not explicitly stated, route of administration was only to
the mother (either ante-natal or post-natal transfer in breast
milk) or if route of administration of erythromycin was
ambiguous. When more than one publication from an over-
lapping cohort was identified, the largest study with the most
rigorous methodology was selected. Duplicate data, already
available as a published paper, which had been published in
the form of letters to the editor of journals was also excluded.
The selection process is illustrated in Fig. 1. Data was
independently extracted by the authors.
The meta-analysis was performed using Mantel–Haen-
szel random effects model using the Cochrane Collabora-
tion’s Review Manager (RevMan 5.3, the Nordic Cochrane
Centre, the Cochrane Collaboration, Copenhagen) to cal-
culate the overall odds ratio (OR), 95 % confidence inter-
val (CI) and I2 test statistic for heterogeneity of studies.
Publication bias was assessed using the funnel plot
method.
Results
Literature search identified 115 papers for potential inclu-
sion; 104 did not meet the criteria for inclusion and were
excluded from the meta-analysis (Fig. 1). The remaining
nine studies comprised two randomised control trials (one
study on erythromycin used for improving enteral feeding
tolerance and a second study on oral erythromycin for
treatment of gastrointestinal dysmotility in preterm
infants), and seven retrospective cohort studies. The char-
acteristics of eligible studies are shown in Table 1.
Selected cohort studies were published between 1999
and 2016. Cases were defined as infants who developed
pyloric stenosis in infancy (age less than 6 months),
whilst controls were patients who did not develop pyloric
stenosis during the study period. National birth registries,
hospital and community health records were the main data
sources for both groups. Diagnosis of pyloric stenosis was
confirmed from clinical diagnosis recorded in health
records. The total number of infants included was
3,008,453, of whom 16,431 had received erythromycin.
Sixty-three infants developed IHPS after receiving ery-
thromycin, whereas 4632 infants developed IHPS without
having received erythromycin. In the two randomised
studies, the total number of infants included was small,
and there were no cases of pyloric stenosis in either the
exposed or the unexposed groups, so that they could not
contribute to the odds ratio. Overall, there was a signifi-
cant association between erythromycin exposure and
subsequent development of pyloric stenosis [OR 2.45
(1.12–5.35), p = 0.02, Fig. 2]. However, there was sig-
nificant heterogeneity between the studies (I2 = 84 %,
p\ 0.0001). A funnel plot of published studies demon-
strated possible asymmetry indicating potential publica-
tion bias, although asymmetry is difficult to determine
with only seven studies contributing to the funnel plot
(Fig. 3).
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Fig. 1 Diagram of workflow in the systematic review and meta-
analysis
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A further analysis was performed to identify the rela-
tionship between exposure to erythromycin in the first
14 days of life and development of IHPS. Only four of the
selected nine studies documented whether exposure had
occurred within this period. In these studies, the association
between erythromycin exposure and subsequent develop-
ment of pyloric stenosis was even stronger [OR 12.89
(7.67–2167), p\ 0.00001] (Fig. 4).
Discussion
This study is the only published meta-analysis which
reviews the association between erythromycin use in
infants and subsequent development of IHPS and provides
a comprehensive estimate of this risk.
The key finding of the meta-analysis is that the OR of
developing IHPS after any erythromycin in the post-natal
Table 1 A summary of the studies included detailing country of origin, study type, data source, total number of infants studied, number of
infants within study group who were exposed to erythromycin, and subsequently developed IHPS and the weight of the study in the meta-analysis
Study (year) Country Study type Source of data Total
number
of
infants
Number of infants
exposed to
erythromycin who
developed IHPS
Study
weight
(%)
Ng et al. (2001)
[10]
China Randomised
control
trial
Preterm infants admitted to the neonatal unit at
Prince of Wales Hospital, Hong Kong from
November 1998–May 2000
29 0 /
Cooper et al.
(2002) [11]
United
States
Cohort study Medicaid or TennCare (Tennessee’s program for
Medicaid enrollees and uninsured individuals)
births in Tennessee from 1985–1997
306891 9 18
Eberly et al. (2015)
[12]
United
States
Cohort study Infants born between 1 June 2001 and 1 April
2012 registered with the TRICARE
Management Activity military health system
(MHS) database
1069900 17 19.2
Mahon et al.
(2001) [13]
United
States
Cohort study Infants born from 1 June 1993–31 December
1999, Wishard Hospital, Indianapolis
14407 4 15
Honein et al.
(1999) [14]
United
States
Cohort study Infants born in a community hospital from
January–February 1999
125 7 5.3
Ludvigsson et al.
(2016) [9]
Sweden Cohort study Nationwide cohort of infants born between July
2005 and December 2010
582256 0 5.5
Ericson et al.
(2015) [15]
United
States
Cohort study Infants from 348 NICUs managed by the
Pediatrix Medical Group between 1997–2012
19001 10 17.9
Lund et al. (2014)
[16]
Denmark Cohort study All liveborn singleton infants in Denmark
between 1 January 1996 and 31 December
2011
999378 16 19.1
Mohammadizadeh
et al. (2010) [17]
Iran Randomised
control
trial
Uncomplicated preterm infants (28–34 weeks)
born in Shahid-Beheshti and Al-Zahra
Hospitals affiliated with the Isfahan University
of Medical Sciences
35 0 /
Fig. 2 Forest plot comparing the incidence of IHPS between infants with exposure to erythromycin at any time and infants who had never been
exposed to erythromycin
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period is two and a half (OR = 2.45) times greater than in
those infants not exposed to the drug. Furthermore, sub-
group analysis of included studies identified a 12-fold
increase in the development of IHPS when erythromycin
was administered in the first 14 days of life; a value sig-
nificantly higher than previously reported.
Literature search did not identify any published meta-
analyses and only one systematic review. Maheshwa et al.
[7] investigated the relationship between young infants
treated with erythromycin and risk of developing hyper-
trophic pyloric stenosis by analysis of six papers published
between 1976 and 2005. Their review concludes that while
more evidence is required regarding the relationship
between erythromycin use and IHPS, young infants
exposed to erythromycin in the first few weeks of life are at
a greater risk of IHPS. Their analysis is also in agreement
with this study in stating that the risk appears to be highest
in the first 2 weeks of life, but stipulates that this occurs in
term or near-term infants or when antibiotics are admin-
istered for more than 14 days.
It should be noted that two papers included in our
analysis, Ng et al. [10] and Mohammadizadeh et al. [17],
study populations of preterm infants alone whilst Ericson
et al. [15] have analysed only infants within a neonatal
intensive care (NICU) environment. Therefore, variability
of the calculated OR may occur due to the inclusion of
these groups of infants within the analysis. This could also
explain the high I2 value representing heterogeneity.
In addition, significant geographical bias exists with five
of the nine studies selected for analysis focusing on pop-
ulations from the United States. Such bias may partly result
from the literature search criteria which only include
studies published in the English language.
A further source of bias occurs due to the greater pro-
portion of cohort studies included for analysis in compar-
ison to other study types. There were no published case–
control studies which reviewed this relationship. However,
this may result from the ethical feasibility of designing a
study which may prevent an infant from receiving ery-
thromycin to treat infection in cases where alternative
antibiotics are contraindicated or insensitive.
Bias
In accounting for the variability of the calculated OR and
the significant heterogeneity present between the nine
included studies, several factors must be considered. An
important factor is that the incidence of IHPS is hetero-
geneous, varying significantly according to ethnicity, sex
and time. There is also a significant genetic component to
development of IHPS, so that any conclusive study should
also include analysis of confounders, such as gender, eth-
nicity, and genetic status.
Risk/benefit
Erythromycin is commonly indicated within the neonatal
population for prophylaxis following Chlamydia tra-
chomatis infection [18] in preventing conjunctivitis or
pneumonia and in the treatment of pertussis [14]. In
addition, erythromycin has also been utilised in the treat-
ment of gastrointestinal dysmotility within this population
[10].
Although this study concludes that OR for developing
IHPS following erythromycin exposure is high, particularly
Fig. 3 Funnel plot of included studies
Fig. 4 Forest plot comparing the incidence of IHPS between infants with exposure to erythromycin within the first 2 weeks of life and infants
who have never been exposed to erythromycin
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in the first 14 days of life, physicians must evaluate the
risk–benefit ratio in making an informed decision as to
whether the potential morbidity or mortality of an infection
such as pertussis is outweighed by the risk of developing
IHPS. It should also be noted that the absolute risk of
developing IHPS following erythromycin exposure is not
high [0.4 % (95 % CI 0.3–0.5 %) in those receiving ery-
thromycin at any time, and 2.6 % (95 % CI 1.5–4.2 %) in
those receiving erythromycin in the first 14 days]. How-
ever, consideration should be made to the fact that despite
the indications, macrolides (including erythromycin)
remain unlicensed for use by the US Food and Drug
Administration for use in infants less than 6 months.
Limitations
The main limitation of this study is the lack of published
studies investigating the relationship between erythromycin
use and development of IHPS. Furthermore, differences
existed between study designs which may have led to
further variability in the calculated ORs. In particular,
studies often categorised cases into time periods which
often varied between studies resulting in their exclusion
despite rigorous methodology. Studies which did not
explicitly state that the macrolide administered was ery-
thromycin were also excluded. In addition, all cohort
studies included were performed retrospectively, thus
having a negative effect on the quality of the data. Our
study aimed to exclusively review the effect of neonatal
administration of erythromycin on the risk of subsequently
developing IHPS. However, the question remains as to
whether other methods of exposure (such as maternal
administration en-utero or postnatally from absorption via
breast milk) may be associated with similar levels of risk.
With regard to exposure via breastfeeding, Sorensen [19]
concludes that an increased risk of developing IHPS exists
following maternal macrolide administration postnatally
[OR 2.7 (95 % CI 0.7–11.1)]. However, this is contrasted
by two papers by [20] Goldstein et al. and [21] Salman
et al. which found no correlation between breast milk
exposure and IHPS. The data on exposure via breast milk
was too sparse to meta-analyse.
There is also some evidence in the literature that
administration of erythromycin to pregnant women may
result in the fetus developing IHPS as an infant. Kallen [22]
report a risk ratio of 2.51 (95 % CI 0.92–5.46) of infants
developing IHPS in cases where their mother had received
erythromycin after the first antenatal visit. However, studies
by Lin [23] and Louik [24] found no relationship between
prenatal exposure to macrolide and pyloric stenosis.
Furthermore, from the papers analysed, there is no
report regarding the family history, and therefore it remains
unclear if a genetic predisposition is required to increase
the risk of acquiring IHPS following administration of
erythromycin. With such significant variability in the
available literature in reporting the exact nature and mag-
nitude of risk of erythromycin administration (during both
fetal and neonatal development) further study is warranted.
Conclusion
This study provides clinicians with the first comprehensive
estimate for the OR of infants developing IHPS when
exposed to erythromycin. Physicians should utilise this
study as a tool in evaluating the risk–benefit ratio of
administering erythromycin for treatment and prophylaxis
of infections in neonates versus the risk of developing
IHPS. However, in determining whether erythromycin is a
suitable treatment for infections within this group, the
limitations of this study should be noted. In particular,
publications bias and the lack of high-quality, with sig-
nificant patient numbers should be considered.
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